Treatment of Severe Candida Infections in High-Risk Patients in Germany: Consensus Formed by a Panel of Interdisciplinary Investigators

[1]  J. Cantú.  Hepatosplenic Candidiasis in Patients with Acute Leukemia , 2004 .

[2]  A. Schwarer,et al.  Intravenous and Oral Itraconazole versus Intravenous Amphotericin B Deoxycholate as Empirical Antifungal Therapy for Persistent Fever in Neutropenic Patients with Cancer Who Are Receiving Broad-Spectrum Antibacterial Therapy , 2001, Annals of Internal Medicine.

[3]  W. Hiddemann,et al.  Acute myeloid leukaemia (AML): treatment of the older patient. , 2001, Best practice & research. Clinical haematology.

[4]  E. Buescher,et al.  Should Central Venous Catheters Be Removed as Soon as Candidemia Is Detected in Neonates? , 2000, Pediatrics.

[5]  L. See,et al.  Clinical Correlates of Antifungal Macrodilution Susceptibility Test Results for Non-AIDS Patients with Severe CandidaInfections Treated with Fluconazole , 2000, Antimicrobial Agents and Chemotherapy.

[6]  S. Piscitelli,et al.  Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. , 2000, The Journal of infectious diseases.

[7]  A. Ganser,et al.  Hepatosplenic candidiasis in patients with acute leukaemia , 2000, British journal of haematology.

[8]  J. Sobel,et al.  Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  L. Saiman,et al.  Risk factors for candidemia in Neonatal Intensive Care Unit patients , 2000, The Pediatric infectious disease journal.

[10]  D. Andes,et al.  In Vivo Characterization of the Pharmacodynamics of Flucytosine in a Neutropenic Murine Disseminated Candidiasis Model , 2000, Antimicrobial Agents and Chemotherapy.

[11]  M. Territo,et al.  A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. , 2000, The American journal of medicine.

[12]  T. Büchner,et al.  Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine , 1999, Mycoses.

[13]  G. Noel,et al.  Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. , 1999, The Journal of pediatrics.

[14]  L. Saiman,et al.  National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  B. Lebeau,et al.  Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  N. Kröger,et al.  Early infections in patients undergoing bone marrow or blood stem cell transplantation – a 7 year single centre investigation of 409 cases , 1999, Bone Marrow Transplantation.

[17]  M. Pfaller,et al.  Trends in Antifungal Use and Epidemiology of Nosocomial Yeast Infections in a University Hospital , 1999, Journal of Clinical Microbiology.

[18]  T. Walsh,et al.  Current approaches to diagnosis and treatment of fungal infections in children infected with human immuno deficiency virus , 1999, European Journal of Pediatrics.

[19]  L. Collette,et al.  An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  Carpenter,et al.  Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  A. Ganser,et al.  Hepatic lesions of chronic disseminated systemic candidiasis in leukemia patients may become visible during neutropenia: value of serial ultrasound examinations. , 1998, Blood.

[22]  E. Anaissie,et al.  Predictors of adverse outcome in cancer patients with candidemia. , 1998, The American journal of medicine.

[23]  E. Anaissie,et al.  Importance of Candida species other than Candida albicans as opportunistic pathogens. , 1998, Medical mycology.

[24]  S. Piscitelli,et al.  Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. , 1998, Advances in pharmacology.

[25]  G. Krestin,et al.  Hepatic lesions of chronic disseminated candidiasis may become invisible during neutropenia. , 1997, Blood.

[26]  A. Penk,et al.  High‐dose therapy with fluconazole ≥ 800 mg day‐1 , 1997, Mycoses.

[27]  M. Ghannoum,et al.  International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  H. Einsele,et al.  Detection and identification of fungal pathogens in blood by using molecular probes , 1997, Journal of clinical microbiology.

[29]  M. Trautmann,et al.  In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection , 1997, Antimicrobial agents and chemotherapy.

[30]  A. Penk,et al.  Plasma and tissue concentrations of fluconazole and their correlation to breakpoints , 1997, Mycoses.

[31]  C. Rotstein,et al.  Guidelines for the Management of Nosocomial Candida Infections in Non-Neutropenic Intensive Care Patients , 1997 .

[32]  E. Anaissie,et al.  Update on invasive candidiasis. , 1997, Advances in pharmacology.

[33]  W. Hiddemann,et al.  Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effects. , 1997, Seminars in oncology.

[34]  A. Ganser,et al.  A Randomized , Double-Blind , Placebo-Controlled , Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia , 1997 .

[35]  M. Trautmann,et al.  Comparative evaluation of three antifungal susceptibility test methods for Candida albicans isolates and correlation with response to fluconazole therapy , 1996, Journal of clinical microbiology.

[36]  E. Anaissie,et al.  Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  A. Dauber,et al.  A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemicCandida infections in intensive care patients , 1996, Infection.

[38]  C. Viscoli,et al.  Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. , 1996, European journal of cancer.

[39]  S. Chanock,et al.  Invasive fungal infections in children: recent advances in diagnosis and treatment. , 1996, Advances in pediatric infectious diseases.

[40]  D. Snydman,et al.  Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. , 1995, Archives of internal medicine.

[41]  A. Karchmer,et al.  Fungal infections in solid organ transplant recipients. , 1995, Infectious disease clinics of North America.

[42]  J. Serody,et al.  Intravascular Catheter Exchange and Duration of Candidemia , 1995 .

[43]  J. Vincent,et al.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. , 1995, JAMA.

[44]  Stephen L. George,et al.  Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia , 1995 .

[45]  W. Jarvis.  Epidemiology of nosocomial fungal infections, with emphasis on Candida species. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  M. Kalin,et al.  Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever--preliminary observations from a pilot, exploratory study. , 1995, The Journal of infection.

[47]  S. Walmsley,et al.  Use of fluconazole in the treatment of candidal endophthalmitis. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  S. Hinrichs,et al.  Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  J. Rex,et al.  Resistance of Candida species to fluconazole , 1995, Antimicrobial agents and chemotherapy.

[50]  J. Rex,et al.  Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group , 1995, Antimicrobial agents and chemotherapy.

[51]  F. Meunier,et al.  Special aspects related to invasive fungal infections in children with cancer. , 1995 .

[52]  J. Wingard,et al.  Importance of Candida species other than C. albicans as pathogens in oncology patients. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  R. Auckenthaler,et al.  Candida Colonization and Subsequent Infections in Critically III Surgical Patients , 1994, Annals of surgery.

[54]  M. Levenstein,et al.  A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia , 1994 .

[55]  W. Hiddemann,et al.  Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study , 1994, Cancer.

[56]  B. Doebbeling,et al.  Investigation of the sequence of colonization and candidemia in nonneutropenic patients , 1994, Journal of clinical microbiology.

[57]  Management of deep Candida infection in surgical and intensive care unit patients. British Society for Antimicrobial Chemotherapy Working Party. , 1994, Intensive care medicine.

[58]  F. Mandelli,et al.  Fungemia in Patients with Leukemia , 1993, The American journal of the medical sciences.

[59]  J. Wingard,et al.  Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients , 1993, Antimicrobial Agents and Chemotherapy.

[60]  B. Schneeweiss,et al.  Clinical Measures of Islet Function: Usefulness to Characterize Defects in Diabetes , 1993 .

[61]  B. Schneeweiss,et al.  Treatment of Candida albicans fungaemia with fluconazole. , 1993, The Journal of infection.

[62]  T. Walsh,et al.  Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. , 1992, The Journal of pediatrics.

[63]  J. Mueller.  Resistance phenomena to systemic antimycotic drugs and the problem of susceptibility testing , 1992 .

[64]  S. Steinberg,et al.  Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[65]  C. Prober,et al.  Prophylactic fluconazole and Candida krusei infections. , 1992, The New England journal of medicine.

[66]  M G Rinaldi,et al.  Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. , 1991, The New England journal of medicine.

[67]  E. Anaissie,et al.  Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. , 1991, The American journal of medicine.

[68]  D. R. Weber,et al.  Hepatosplenic candidiasis: successful treatment with fluconazole. , 1991, The American journal of medicine.

[69]  W. Hiddemann,et al.  Antifungal treatment by amphotericin B and 5‐fluorocytosine delays the recovery of normal hematopoietic cells after intensive cytostatic therapy for acute myeloid leukemia , 1991, Cancer.

[70]  E. Helm,et al.  Fluconazole in the treatment of oropharyngeal candidosis in HIV‐positive patients , 1990, Mycoses.

[71]  P. Spagnuolo,et al.  Emergence of a new opportunistic pathogen, Candida lusitaniae , 1989, Journal of clinical microbiology.

[72]  F. Meunier.  Empirical antifungal therapy in febrile granulocytopenic patients , 1989 .

[73]  T. Shawker,et al.  Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. , 1988, Annals of internal medicine.

[74]  L. Frankel,et al.  Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  W. Merz.  Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance , 1984, Journal of clinical microbiology.

[76]  S. Lipton,et al.  Candidal infection in the central nervous system. , 1984, American Journal of Medicine.

[77]  R. Guinet,et al.  Fatal septicemia due to amphotericin B-resistant Candida lusitaniae , 1983, Journal of clinical microbiology.

[78]  W. Lee,et al.  Fungal infections in patients with acute leukemia. , 1982, The American journal of medicine.

[79]  F. Witebsky,et al.  Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. , 1982, The American journal of medicine.

[80]  G. Bodey.  Fungal infections complicating acute leukemia. , 1966, Journal of chronic diseases.